Compare GNT & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | NYXH |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.6M | 165.0M |
| IPO Year | N/A | 2021 |
| Metric | GNT | NYXH |
|---|---|---|
| Price | $9.00 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 44.6K | ★ 250.6K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | $9.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.68 | $1.26 |
| 52 Week High | $9.38 | $6.87 |
| Indicator | GNT | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 39.88 |
| Support Level | $7.77 | $1.28 |
| Resistance Level | $9.29 | $1.70 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 17.11 | 2.08 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.